aTyr PharmaATYR +2.08%14 3-Year ROIIC % is 1,279.63 as of Dec. 2025. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,324 Biotechnology companies, aTyr Pharma ranks better than 94.79% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
aTyr Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1,279.63%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for aTyr Pharma's 3-Year ROIIC % or its related term are showing as below:
ATYR's 3-Year ROIIC % is ranked better than 94.79% of 1324
companies
in the Biotechnology industry
Industry Median: -4.42
vs ATYR: 1279.63
aTyr Pharma (NAS:ATYR) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
aTyr Pharma 3-Year ROIIC % Related Terms
aTyr Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATYR vs DWTX, CNTX, INKT: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, aTyr Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's 3-Year ROIIC % falls into.
aTyr Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -77.627 (Dec. 2025) - -46.404 (Dec. 2022) )
/
( 14.232 (Dec. 2025) - 16.672 (Dec. 2022) )
=
-31.223
/
-2.44
=
1,279.63%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
aTyr Pharma (ATYR) has a 3-Year ROIIC % of 1,279.63 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on aTyr Pharma and its competitors. According to the industry distribution chart, aTyr Pharma ranks #69 out of 1324 companies in the Biotechnology industry, placing it in the top 5.2%.
Is aTyr Pharma's 3-Year ROIIC % too high?
aTyr Pharma's current 3-Year ROIIC % is 1,279.63. Based on the distribution chart, aTyr Pharma ranks #69 out of 1324 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's 3-Year ROIIC % compare to DWTX and CNTX?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #69 out of 1324 companies for 3-Year ROIIC %. This places aTyr Pharma in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on aTyr Pharma and its competitors. aTyr Pharma's current 3-Year ROIIC % is 1,279.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.59 — trading 29.1% above its estimated fair value. The current 3-Year ROIIC % is 1,279.63. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current 3-Year ROIIC % is 1,279.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.59 is trading 29.1% above its estimated GF Value™ of $0.46.
GuruFocus considers aTyr Pharma to be Modestly Overvalued.
Key valuation signals for ATYR:
3-Year ROIIC %: 1,279.63
GF Value™: $0.46 vs. price of $0.59 (29.1% above fair value)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
